Objective To investigate the associated factors of complete virological response (CVR) in Entecavir treatment among chronic hepatitis B (CHB) patients with positive HBeAg.Methods Data of 166 CHB patients with positive HBeAg receiving Entecavir treatment in Yantai Infectious Diseases Hospital during December 2009 and May 2014 were collected.Clinical data including age,gender,genotype,baseline alanine aminotransferase (ALT),HBV DNA load,HBsAg and HBeAg levels as well as CVR cumulative rates at different time points during Entecavir treatment were retrospectively analyzed.The cumulative rate of CVR was estimated using Kaplan-Meier method,and the difference in cumulative CVR rates was studied with Log-rank test.Cox's proportional hazards regression model was used to analyze the factors associated with CVR during Entecavir treatment.Results The cumulative rates of CVR during Entecavir treatment in HBeAg positive CHB patients were 54.5％ (87/157),74.3％ (106/129),80.2％ (109/119) and 86.8％ (110/112) at 48,96,144 and 192 weeks,respectively.Log-rank test showed that female patients and patients with genotype B,high baseline ALT level or low baseline HBV DNA load had higher CVR rates (x2 =15.601,11.542,17.021 and 10.094,all P ＜ 0.01).Cox's proportional hazards regression model showed that female was the only associated factor for CVR in Entecavir treatment among HBeAg positive CHB patients [hazard ratio (HR) =3.015,95％ confidence interval (CI):1.875-4.968,P ＜ 0.01].Conclusion CVR rate is increasing with the course of Entecavir treatment in HBeAg positive CHB patients,and CVR is more likely to occur in female patients.

Objective To compare the cumulative rate of HBeAg seroconversion in HBeAg positive chronic Hepatitis B patients treated with telbivudine and entecavir after Propensity Score Matching.Methods CHB patients who accepted telbivudine or entecavir from Dec 2009 to May 2014 were retrospectively collected.PSM function of SPSS software was conducted to reduce confounding bias between the groups.And then survival analysis was performed for the matched data.Results 56 pairs of patients were successfully matched.The 2-year cumulative rate of HBeAg seroconversion were 28.6％ and 14.8％ in the telbivudine group and entecavir group,which were 42.0％ and 39.3％ in the fourth year respectively.Cox regression analysis revealed that telbivudine therapy,low HBeAg level at baseline were independent predict factors of HBeAg seroconversion(P ＜ 0.05).Conclusions The balance of covariates may be achieved through PSM.The 2-year cumulative rate of HBeAg seroconversion in the telbivudine group is higher than entecavir group,while they are similar in the 4th year.